Titlebook: Receptor-Mediated Targeting of Drugs; G. Gregoriadis,G. Poste,A. Trouet Book 1984 Springer Science+Business Media New York 1984 biology.en

Ancestor

activation or by their inability to interact with or reach target sites efficiently. New trends in pharmacology empha- size the development of methods for the optimization of drug action, for instance by the delivery of drugs, enzymes, hormones, antigens, genetic material, ets. through carrier syste

infelicitous

Drug Targeting in Human Cancer Chemotherapy,ough a covalent bond to macromolecular carriers which are recognized by receptors or antigens present at the cell surface of the target cells and thereafter endocytosed to allow the release of the drug after hydrolysis of the covalent linkage by lysosomal enzymes.

seduce

民間傳說(shuō)

Monoclonal Antibodies as Cell Targeted Carriers of Covalently and Non-Covalently Attached Toxins, active toxic portion, these components can be cleaved and isolated (Olsnes and Pihl, 1973). Thus, purified toxic subunits can be coupled to antibodies to produce highly selective cytotoxic agents which are devoid of residual toxin binding.

CHOP

Endocytosis of Liposomes and Intracellular Fate of Encapsulated Molecules: Strategies for Enhanced ecently, several groups have shown that it is possible to couple covalently to the liposome surface a variety of ligands, such as immunoglobulins, to promote specificity of lipo-some-cell interaction and to increase the number of liposomes bound to or internalized by cells (Heath et al., 1980; Leserman et al., 1980; Heath et al., 1983).

宴會(huì)

Servile

The Use of Liposomes in Diagnostic Imaging,f, the route (including the administration route and the path between the site of administration and the final destination) and the target tissue. Drug carriers, route and target have specific chemical, physical and anatomical features that deserve special consideration.

Hyperplasia

Drug Targeting in Human Cancer Chemotherapy,itable side effects resulting from an interaction of the drugs with non target cells and, on the other hand, enhance the pharmacological activity by increasing the proportion of the administered drug found within the target cells. Our conceptual approach to this problem consists in linking drugs thr

詩(shī)集

Toxic Conjugates of Epidermal Growth Factor and Asialofetuin, cell surface receptors and initiate a cascade of biological responses leading either to cell division or expression of a new phenotype as a consequence of ligand-receptor interactions. In many cases one of the most notable initial responses is ligand-induced endocytosis of the receptor-ligand compl

Nucleate

Saccharide Receptor-Mediated Drug Delivery,ccepted that exposed sugar residues on glycoproteins serve as determinants for in-vivo (i.e., clearance) and in-vitro (i.e., uptake) recognition. Carbohydrate-mediated endocytosis in mammals has since become the subject of intensive studies.. Mammalian hepatic receptors are known to be specific for